Shepherd Kaplan Krochuk’s Galmed Pharmaceuticals GLMD Stock Holding History

Shepherd Kaplan Krochuk’s Portfolio GLMD Stock Details GLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-13	Closed	-$167K	–	255
2017 Q3	$167K	Hold	13	–	–	0.14%	160
2017 Q2	$114K	Buy	+13	New	+$97.9K	0.07%	192
2017 Q1	–	Sell	-20	Closed	-$101K	–	268
2016 Q4	$101K	Sell	20 -2	-9%	-$10.6K	0.03%	227
2016 Q3	$142K	Hold	22	–	–	0.03%	280
2016 Q2	$144K	Hold	22	–	–	0.04%	271
2016 Q1	$158K	Buy	22 +9	+69%	+$70.6K	0.05%	217
2015 Q4	$142K	Sell	13 -13	-50%	-$166K	0.04%	318
2015 Q3	$278K	Hold	26	–	–	0.07%	195
2015 Q2	$376K	Hold	26	–	–	0.07%	205
2015 Q1	$352K	Hold	26	–	–	0.06%	215
2014 Q4	$217K	Hold	26	–	–	0.03%	329
2014 Q3	$321K	Sell	26 -10	-28%	-$109K	0.04%	296
2014 Q2	$504K	Buy	36 +18	+100%	+$221K	0.05%	220
2014 Q1	$297K	Buy	+18	New	+$337K	0.03%	316

Other funds holding GLMD

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Ibex Investors Denver, Colorado $194M AUM 23.58% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PAWC

P.A.W. Capital Greenwich, Connecticut $131M AUM 35.16% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Shepherd Kaplan Krochuk's GLMD Position: Q4 2017 in Review

Shepherd Kaplan Krochuk sold out of Galmed Pharmaceuticals (GLMD) in Q4 2017, closing a stake of 13 shares — an estimated $167K sold.

Shepherd Kaplan Krochuk first reported a position in GLMD in Q1 2014 and held it in 14 quarters. The position peaked at $504K in Q2 2014. 18 funds tracked by Wall St. Rank hold GLMD as of Q4 2017.

Shepherd Kaplan Krochuk reported no remaining Galmed Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
Shepherd Kaplan Krochuk sold 13 Galmed Pharmaceuticals shares in Q4 2017, an estimated $167K.
Shepherd Kaplan Krochuk first reported a position in Galmed Pharmaceuticals in Q1 2014 and held it in 14 quarters.
Shepherd Kaplan Krochuk's Galmed Pharmaceuticals position peaked at $504K in Q2 2014.
18 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q4 2017.

Based on Shepherd Kaplan Krochuk's 13F filing for Q4 2017, filed 13 Feb 2018.